LIST OF TABLES

List of Tables

Table 1: Symptoms related to allergic conjunctivitis, bacterial conjunctivitis and viral conjunctivitis ............................................................ 2
Table 2: Antibiotics prescribed in acute bacterial conjunctivitis .................. 4
Table 3: Prevalence of Bacterial Keratitis in different parts of world .......... 6
Table 4: Treatment options for Bacterial Keratitis ..................................... 9
Table 5: Formulation strategies to increase bioavailability of ocular formulations ...... 35
Table 6: Literature search carried out for SLNs ocular drops .................... 37
Table 7: A recently used techniques for various researchers in preparation of SLNs ...... 39
Table 8: Recent research on In-situ gelling systems ........................................... 41
Table 9: Dispersed system combination with in-situ gel ............................... 42
Table 10: Application of QbD in SLNs development ....................................... 44
Table 11: Research in Moxifloxacin ocular formulations to improve pre-corneal residence time and improved permeability ........................................ 48
Table 12: Commercial extended release formulation .................................... 51
Table 13: Chemicals and materials used ......................................................... 55
Table 14: List of Equipments Used ................................................................. 56
Table 15: QTPP for Moxifloxacin lipid based in-situ gel system ................. 60
Table 16: Critical quality attributes (CQAs) for Moxifloxacin lipid based in-situ gel system ................................................................. 60
Table 17: Screening carried out to determine potential process parameters on CQAs ..... 61
Table 18: Independent variables and their levels in CCD Design ................... 62
Table 19: Independent variables and their levels in BBD Design .................. 62
Table 20: Specifications for Texture profile analysis ..................................... 68
Table 21: Sequence of in-vivo activities followed and number of animals at each stage . 71
Table 22: Results of method development carrier out for MOX in Methanol, TDM and STF ..................................................................................................................................... 77
Table 23: Mean & SD results for Repeatability & Intermediate Precision for MOX during UV method development ................................................................................................... 79
Table 24: Results of accuracy as recovery studies ................................................................................................................................. 80
Table 25: Results of drug excipient compatibility studies ................................................................................................................................. 81
Table 26: REM for initial risk assessment (Process Component) ................................................................................................................................. 83
Table 27: REM for initial risk assessment (Formulation Component) ......................................................................................................................... 83
Table 28: Compilation of factor screening studies and its results ................................................................................................................................. 85
Table 29: Impact of process parameter on CQA (particle size) ................................................................................................................................. 86
Table 30: Statistical analysis of entrapment efficiency, Particle size and outlet formulation temperature ................................................................................................................................. 90
Table 31: Evaluation of gelling parameters for formulations with varying concentration of Poloxamer 407 ..................................................................................................................................... 96
Table 32: Statistical analysis of entrapment efficiency, Particle size and outlet formulation temperature ..................................................................................................................................... 97
Table 33: Results (mean ± SD) obtained for formulation optimization studies ................................................................................................................................. 104
Table 34: Release kinetics calculations carried out on optimization design formulations ................................................................................................................................. 106
Table 35: Ex vivo corneal permeability data of design space formulation wrt to IR solution in terms of cumulative amount permeated (µg) at each time interval (h) ..................................................................................................................................... 108
Table 36: Comparison of design space formulation in terms of total amount permeated, % permeation and apparent permeability co-efficient Papp from ex vivo permeation studies using goat cornea ..................................................................................................................................... 109
Table 37: Gelling temperature and gelling time observed for design space formulations ..................................................................................................................................... 111
List of Tables

Table 38: Gelling concentration reported by other researcher for Poloxamer 407 alone or in combination ................................................................. 112
Table 39: Viscosity, pH and osmolarity observed for selected formulation .......... 114
Table 40: Compilation of texture properties for design space formulations .......... 115
Table 41: Compilation of topical properties for design space formulation .......... 116
Table 42: Impact on CQAs on hold time stability .................................................. 116
Table 43: Results of CQAs before freeze drying, after freeze drying and sterilization at two points ................................................................. 119
Table 44: Results of CQAs for formulation OPT-07-1 till use after redispersion .... 119
Table 45: Positive control (growth promotion test) for sterility testing ................. 120
Table 46: Visual observation of turbidity in sterility testing .................................. 121
Table 47: Comparative evaluation of Antimicrobial efficacy for optimized formulation OPT-07-1 wrt to Marketed formulation Moxicip (cipla) .............. 135
Table 48: Score of acute dermal irritation/corrosion study of formulation in rabbit skin 136
Table 49: Score of single installation acute eye irritation/corrosion study of formulation OPT-07-1 in rabbit eye ................................................................. 136
Table 50: Score of repeat installation acute eye irritation/corrosion study of formulation OPT-07-1 in rabbit eye ................................................................. 137
Table 51: Score of chronic repeat (5 instillations at 5 min interval) for one week after installation of optimized formulation OPT-07-1 ........................................ 137
Table 52: Score index the eyes infected with *S. aureus* for control group, treatment with marketed formulation and after treatment with Hybrid formulation OPT-07-1 at initial, day 1, 3 & 5th day of treatment ................................................................. 140
Table 53: Statistical analysis carried out p values ................................................. 140
Table 54: Score index the eyes infected with *S. aureus* for control group, treatment with marketed formulation and after treatment with Hybrid formulation OPT-07-1 at initial, day 1, 3 & 5th day of treatment ................................................................. 143
Table 55: Statistical analysis carried out p values ........................................................... 144
Table 56: Stability studies carried out for OPT-07-1 formulation 25°C/60%RH ............ 146
Table 57: Stability studies carried out for OPT-07-1 formulation 5°C±3°C.................... 147